LT97200A - N-propargil-1-aminoindano r-entantiomero, jo druskų ir jo kompozicijų panaudojimas - Google Patents
N-propargil-1-aminoindano r-entantiomero, jo druskų ir jo kompozicijų panaudojimasInfo
- Publication number
- LT97200A LT97200A LT97-200A LT97200A LT97200A LT 97200 A LT97200 A LT 97200A LT 97200 A LT97200 A LT 97200A LT 97200 A LT97200 A LT 97200A
- Authority
- LT
- Lithuania
- Prior art keywords
- aminoindan
- propargyl
- enantiomer
- salts
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- RUOKEQAAGRXIBM-UHFFFAOYSA-N n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2C(NCC#C)CCC2=C1 RUOKEQAAGRXIBM-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/446,439 US5744500A (en) | 1990-01-03 | 1995-05-22 | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LT97200A true LT97200A (lt) | 1998-09-25 |
| LT4455B LT4455B (lt) | 1999-01-25 |
Family
ID=23772591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LT97-200A LT4455B (lt) | 1995-05-22 | 1997-12-22 | N-propargil-1-aminoindano r-entantiomero, jo druskų ir jo kompozicijų panaudojimas |
Country Status (21)
| Country | Link |
|---|---|
| US (6) | US5744500A (lt) |
| EP (1) | EP0828485A4 (lt) |
| JP (1) | JP3341898B2 (lt) |
| KR (1) | KR100412154B1 (lt) |
| CN (1) | CN1096853C (lt) |
| AU (1) | AU699090B2 (lt) |
| BR (1) | BR9608733A (lt) |
| CA (1) | CA2221458A1 (lt) |
| CZ (1) | CZ288724B6 (lt) |
| EE (1) | EE03741B1 (lt) |
| HU (1) | HUP9901629A3 (lt) |
| IL (1) | IL118247A (lt) |
| LT (1) | LT4455B (lt) |
| LV (1) | LV12083B (lt) |
| MX (1) | MX9708977A (lt) |
| NO (1) | NO975331L (lt) |
| NZ (1) | NZ308866A (lt) |
| PL (1) | PL184124B1 (lt) |
| RU (1) | RU2203653C2 (lt) |
| SK (1) | SK283675B6 (lt) |
| WO (1) | WO1996037199A1 (lt) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744500A (en) * | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| US5844003A (en) * | 1991-04-04 | 1998-12-01 | Innovations Foundation | Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function |
| US5914349A (en) * | 1994-01-10 | 1999-06-22 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| US5726969A (en) * | 1994-12-28 | 1998-03-10 | Matsushita Electric Industrial Co., Ltd. | Optical recording medium having dual information surfaces |
| IL118836A (en) | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
| US7129061B1 (en) * | 1996-08-07 | 2006-10-31 | Biogen Idec Ma Inc. | Tumor necrosis factor related ligand |
| GB9715082D0 (en) * | 1997-07-17 | 1997-09-24 | Scherer Ltd R P | Treatment of attention deficit hyperactivity disorder and narcolepsy |
| US6232326B1 (en) | 1998-07-14 | 2001-05-15 | Jodi A. Nelson | Treatment for schizophrenia and other dopamine system dysfunctions |
| IL149308A0 (en) | 1999-10-27 | 2002-11-10 | Teva Pharma | Use of 1-aminoindan derivatives for treatment of manic disorders |
| DE60231896D1 (de) | 2001-11-05 | 2009-05-20 | Krele Pharmaceuticals Llc | Zusammensetzungen und verfahren zur erhöhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus |
| US20040010038A1 (en) * | 2002-02-27 | 2004-01-15 | Eran Blaugrund | Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors |
| EP1565185A4 (en) * | 2002-11-07 | 2011-01-05 | Technion Res & Dev Foundation | NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH |
| SI1567152T1 (sl) | 2002-11-15 | 2013-10-30 | Teva Pharmaceutical Industries Ltd. | Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze |
| US20040176430A1 (en) * | 2002-11-21 | 2004-09-09 | Jeffrey Sterling | Propargyl-trifluoromethoxy-amino-benzothiazole derivatives |
| CN1605336A (zh) | 2003-10-10 | 2005-04-13 | 中国医学科学院药物研究所 | 左旋丁基苯酞在制备预防和治疗脑梗塞的药物中的应用 |
| WO2005051371A1 (en) | 2003-11-25 | 2005-06-09 | Technion Research & Development Foundation Ltd. | Compositions and methods for treatment of cardiovascular disorders and diseases |
| US8097608B2 (en) * | 2003-11-25 | 2012-01-17 | Technion Research And Development Foundation Ltd. | Methods for treatment of cardiovascular disorders and diseases |
| JP2005232148A (ja) * | 2004-02-03 | 2005-09-02 | Technion Research & Development Foundation Ltd | 神経保護剤としてプロパルギルアミンの使用 |
| US20050197365A1 (en) * | 2004-02-27 | 2005-09-08 | Jeffrey Sterling | Diamino thiazoloindan derivatives and their use |
| WO2006014973A2 (en) * | 2004-07-26 | 2006-02-09 | Teva Pharmaceutical Industries, Ltd. | Pharmaceutical dosage forms including rasagiline |
| US20060025446A1 (en) * | 2004-07-27 | 2006-02-02 | Jeffrey Sterling | Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders |
| WO2006014968A2 (en) * | 2004-07-27 | 2006-02-09 | Teva Pharmaceutical Industries, Ltd. | Propargyl nitroxydes and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders |
| WO2006089095A2 (en) | 2005-02-17 | 2006-08-24 | Biogen Idec Ma Inc. | Treating neurological disorders |
| US20100167983A1 (en) * | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| WO2006089164A1 (en) * | 2005-02-17 | 2006-08-24 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| CA2901244A1 (en) * | 2005-02-23 | 2006-08-31 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations of improved content uniformity |
| EP1848417A1 (en) * | 2005-02-24 | 2007-10-31 | Teva Pharmaceutical Industries Ltd | Formulations of ladostigil tartrate |
| CA2607697C (en) | 2005-05-10 | 2015-01-06 | Biogen Idec Ma Inc. | Treating and evaluating inflammatory disorders |
| WO2006130726A2 (en) * | 2005-06-01 | 2006-12-07 | Teva Pharmaceutical Industries, Ltd. | Use of ladostigil for the treatment of multiple sclerosis |
| FR2886549B1 (fr) * | 2005-06-06 | 2007-09-07 | Biocodex | Composition pharmaceutique destinee a la prevention ou au traitement des oedemes cerebraux |
| US8263655B2 (en) * | 2005-10-06 | 2012-09-11 | Technion Research And Development Foundation Ltd | Methods for treatment of renal failure |
| EP1954667B1 (en) | 2005-11-17 | 2017-02-08 | Teva Pharmaceutical Industries Ltd | Methods for isolating propargylated aminoindans |
| US7572834B1 (en) | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
| US20070135518A1 (en) * | 2005-12-09 | 2007-06-14 | Marta Weinstock-Rosin | Use of low-dose ladostigil for neuroprotection |
| AU2006326642B2 (en) * | 2005-12-09 | 2012-05-03 | Technion Research And Development Foundation Ltd. | Use of low-dose ladostigil for neuroprotection |
| US20110047685A1 (en) * | 2006-02-16 | 2011-03-03 | Ferrara Vincent R | Impact energy management method and system |
| JP5701485B2 (ja) | 2006-02-21 | 2015-04-15 | テバ ファーマシューティカル インダストリーズ リミティド | 多系統萎縮症の治療のためのラサギリンの使用 |
| TW200744576A (en) * | 2006-02-24 | 2007-12-16 | Teva Pharma | Propargylated aminoindans, processes for preparation, and uses thereof |
| CA2646250A1 (en) * | 2006-04-03 | 2007-10-18 | Teva Pharmaceutical Industries Ltd. | Use of rasagiline for the treatment of restless legs syndrome |
| CN101062897B (zh) * | 2006-04-25 | 2011-11-23 | 重庆医药工业研究院有限责任公司 | 一种制备2，3-二氢-1h-茚-1-胺及其衍生物的改进方法 |
| EP1892233A1 (de) * | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| JP5356248B2 (ja) * | 2006-12-14 | 2013-12-04 | テバ ファーマシューティカル インダストリーズ リミティド | ラサギリンのタンニン酸塩 |
| ZA200903903B (en) * | 2006-12-14 | 2010-08-25 | Teva Pharma | Crystalline solid rasagiline base |
| EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| AU2008296908B2 (en) * | 2007-09-05 | 2014-01-09 | Teva Pharmaceutical Industries, Ltd. | Method of treating glaucoma using rasagiline |
| US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
| US20090181086A1 (en) * | 2008-01-11 | 2009-07-16 | Muhammad Safadi | Rasagiline formulations, their preparation and use |
| WO2009118657A2 (en) * | 2008-03-28 | 2009-10-01 | Medichem, S.A. | Polymorphic form of an aminoindan mesylate derivative |
| CN103896779B (zh) * | 2008-06-02 | 2015-12-30 | 基因里克斯(英国)有限公司 | 用于制备对映异构纯胺的方法 |
| WO2009147432A1 (en) * | 2008-06-02 | 2009-12-10 | Generics [Uk] Limited | An improved process for the preparation of amines |
| WO2009151594A1 (en) * | 2008-06-10 | 2009-12-17 | Teva Pharmaceutical Industries, Ltd. | Rasagiline soft gelatin capsules |
| JP2011522892A (ja) * | 2008-06-13 | 2011-08-04 | テバ ファーマシューティカル インダストリーズ リミティド | パーキンソン病緩和のためのラサギリン |
| AU2009260733B2 (en) * | 2008-06-19 | 2015-01-29 | Teva Pharmaceutical Industries, Ltd. | Process for purifying rasagiline base |
| MX2010013875A (es) * | 2008-06-19 | 2011-01-20 | Teva Pharma | Proceso para preparar y secar base de rasagilina solida. |
| EA201170181A1 (ru) | 2008-07-11 | 2011-08-30 | Синтон Бв | Полиморфные формы разагилина гидрохлорида |
| AU2009275665A1 (en) * | 2008-07-30 | 2010-02-04 | Generics [Uk] Limited | Polymorphic form of rasagiline mesylate |
| US20100189790A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
| EP2218444A3 (en) | 2009-01-23 | 2010-08-25 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
| AU2010233694A1 (en) * | 2009-04-09 | 2011-09-29 | Merck Sharp & Dohme B.V. | Indane derivatives |
| SI2451771T1 (sl) | 2009-07-09 | 2014-10-30 | Ratiopharm Gmbh | Soli rasagilina in njihovi farmacevtski pripravki |
| CN102048717B (zh) † | 2009-10-29 | 2014-02-19 | 重庆医药工业研究院有限责任公司 | 一种稳定的雷沙吉兰组合物 |
| EP2325159A1 (en) | 2009-11-24 | 2011-05-25 | LEK Pharmaceuticals d.d. | Novel salts of rasagiline |
| US8741962B2 (en) * | 2009-11-26 | 2014-06-03 | Usv Limited | Process for preparation of Rasagiline and salts thereof |
| AU2010341499A1 (en) * | 2009-12-22 | 2012-08-09 | Teva Pharmaceutical Industries Ltd. | 3-keto-N-propargyl-1-aminoindan |
| RU2607595C2 (ru) | 2010-02-03 | 2017-01-10 | Фарма Ту Б Лтд. | Составы разагилина с пролонгированным высвобождением и их применение |
| ES2608782T3 (es) | 2010-04-30 | 2017-04-17 | Teikoku Pharma Usa, Inc. | Composiciones transdérmicas de propinilaminoindano |
| AU2011282716A1 (en) | 2010-07-27 | 2013-03-14 | Teva Pharmaceutical Industries Ltd. | Dispersions of rasagiline citrate |
| CA2806740A1 (en) | 2010-07-27 | 2012-02-02 | Teva Pharmaceutical Industries Ltd. | Use of rasagiline for the treatment of olfactory dysfunction |
| US20130165511A1 (en) | 2010-09-01 | 2013-06-27 | TONIX Pharmaceuticals Holding Corp | Treatment for cocaine addiction |
| US20120101168A1 (en) | 2010-10-26 | 2012-04-26 | Eliezer Bahar | Deuterium enriched rasagiline |
| WO2012125020A1 (en) * | 2011-03-14 | 2012-09-20 | N.V. Nutricia | Method for treating neurotrauma |
| EP2688561B1 (en) | 2011-03-24 | 2018-08-22 | Teikoku Pharma USA, Inc. | Transdermal compositions comprising an active agent layer and an active agent conversion layer |
| JP2014534197A (ja) | 2011-10-10 | 2014-12-18 | テバ ファーマシューティカル インダストリーズ リミティド | Ｒ（＋）−ｎ−メチル−プロパルギルアミノインダン |
| WO2013055687A2 (en) | 2011-10-10 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | R(+)-n-formyl-propargyl-aminoindan |
| JP5913614B2 (ja) | 2011-11-09 | 2016-04-27 | テイコク ファーマ ユーエスエー インコーポレーテッド | 皮膚新生物の処置方法 |
| EA201491734A1 (ru) | 2012-03-21 | 2015-01-30 | Синтон Бв | Стабилизированные фармацевтические композиции, содержащие соли разагилина |
| WO2013175493A1 (en) | 2012-04-09 | 2013-11-28 | Cadila Healthcare Limited | Stable oral pharmaceutical compositions |
| US9308182B2 (en) | 2012-08-17 | 2016-04-12 | Teva Pharmaceutical Industries, Ltd. | Parenteral formulations of rasagiline |
| AU2013338243B2 (en) | 2012-11-02 | 2016-09-29 | Teikoku Seiyaku Co., Ltd. | Propynylaminoindan transdermal compositions |
| EP2796130A3 (en) * | 2013-02-06 | 2015-02-25 | Galenicum Health S.L. | Immediate release tablets of rasagiline hemitartrate |
| ES2502140T1 (es) * | 2013-02-06 | 2014-10-02 | Galenicum Health S.L. | Comprimidos de liberación inmediata de rasagilina hemitartrato |
| WO2014141280A1 (en) * | 2013-03-13 | 2014-09-18 | Abital Pharma Pipelines Ltd. | Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson's disease |
| CN103804200B (zh) * | 2014-02-21 | 2015-04-29 | 常州市第四制药厂有限公司 | 雷沙吉兰及其类似物的制备方法 |
| CN113924086A (zh) * | 2019-04-17 | 2022-01-11 | 维奇健康科学有限责任公司 | 液体药物组合物 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3201470A (en) * | 1965-08-17 | Chsx c cech | ||
| US513244A (en) * | 1894-01-23 | Island | ||
| US3253037A (en) * | 1962-06-19 | 1966-05-24 | Ciba Geigy Corp | N-2-alkynyl-amino-benzocylo-alkanes |
| GB1187017A (en) | 1966-07-16 | 1970-04-08 | Aspro Nicholas Ltd | Substituted 1-Amino Indanes and Tetrahydronaphthalens |
| GB1037014A (en) | 1963-08-02 | 1966-07-20 | Aspro Nicholas Ltd | Derivatives of 1-aminoindane |
| US3513249A (en) * | 1968-12-24 | 1970-05-19 | Ideal Ind | Explosion connector with improved insulating means |
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| DE252290T1 (de) * | 1986-06-10 | 1988-06-09 | Chiesi Farmaceutici S.P.A., Parma | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. |
| DE3781627T2 (de) | 1986-08-21 | 1993-05-06 | Roussel Uclaf | Indanderivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, diese enthaltende pharmazeutische zusammensetzungen und erhaltene zwischenprodukte. |
| HU197510B (en) | 1986-12-19 | 1989-04-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick |
| US4855326A (en) * | 1987-04-20 | 1989-08-08 | Fuisz Pharmaceutical Ltd. | Rapidly dissoluble medicinal dosage unit and method of manufacture |
| CA1327795C (en) | 1987-08-14 | 1994-03-15 | Jules Freedman | Antidepressants which are aryloxy inadanamines |
| FR2626877B1 (fr) | 1988-02-05 | 1991-04-05 | Delalande Sa | Ethers alkyliques ou benzyliques du phenol, leurs procedes de preparation et leur application en therapeutique |
| HU208484B (en) | 1988-08-17 | 1993-11-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia |
| GB8909793D0 (en) | 1989-04-28 | 1989-06-14 | Beecham Group Plc | Pharmaceutical formulation |
| US5079018A (en) * | 1989-08-14 | 1992-01-07 | Neophore Technologies, Inc. | Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs |
| AU648274B2 (en) | 1989-09-25 | 1994-04-21 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Evaluative means for detecting inflammatory reactivity and for predicting response to stress |
| ES2097155T3 (es) | 1989-10-02 | 1997-04-01 | Cima Labs Inc | Forma de dosificacion efervescente y metodo de administracion. |
| FR2655044B1 (fr) | 1989-11-24 | 1995-03-03 | Delalande Sa | Derives d'(hetero) arylmethyloxy-4 phenyl tetrazole et oxadiazole, leur procede de preparation et leur application en therapeutique. |
| JPH03176457A (ja) | 1989-12-04 | 1991-07-31 | Nippon Paint Co Ltd | 新規プロパルギル化合物、その製法ならびに該化合物を含む被覆材 |
| US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| IL92952A (en) * | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| CA2039742A1 (en) | 1990-04-23 | 1991-10-24 | Andrew B. Dennis | Tablet composition and method for problem pharmaceutical materials |
| US5169868A (en) | 1991-03-01 | 1992-12-08 | University Of Saskatchewan | Aliphatic propargylamines as specific mao-b inhibitors |
| US5844003A (en) * | 1991-04-04 | 1998-12-01 | Innovations Foundation | Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function |
| US5767164A (en) * | 1991-04-04 | 1998-06-16 | Innovations Foundation | Use of deprenyl to rescue damaged nerve cells |
| US5444095A (en) * | 1991-04-04 | 1995-08-22 | University Of Toronto, Innovations Foundation | Use of deprenyl to rescue damaged nerve cells |
| IL99759A (en) | 1991-10-16 | 1997-06-10 | Teva Pharma | Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them |
| JP2807346B2 (ja) * | 1991-12-24 | 1998-10-08 | 山之内製薬株式会社 | 口腔内崩壊製剤及びその製造法 |
| US5298261A (en) * | 1992-04-20 | 1994-03-29 | Oregon Freeze Dry, Inc. | Rapidly distintegrating tablet |
| EP0647133A4 (en) | 1992-06-12 | 1997-10-29 | Affymax Tech Nv | COMPOSITIONS AND METHODS FOR IMPROVED DRUG DELIVERY. |
| SE501848C2 (sv) | 1992-11-18 | 1995-06-06 | Kvaerner Pulping Tech | Metod att koka massa kontinuerligt vid konstant temperatur |
| IL111240A (en) * | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
| IL112779A (en) | 1994-03-01 | 1999-11-30 | Gergely Gerhard | Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation |
| ATE241346T1 (de) | 1995-03-02 | 2003-06-15 | Scherer Technologies Inc R P | Arzneimittel enthaltend monoaminooxidase-b-hemmer |
| IL115357A (en) | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
| IL118836A (en) * | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
| CA2319318A1 (en) * | 1998-01-27 | 1999-07-29 | Thomas N. Thomas | Methods of treatment using mao-a and mao-b inhibitors such as l-deprenyl |
| FI104042B1 (fi) * | 1998-09-29 | 1999-11-15 | Aaro Kiuru | Menetelmä keuhkojen perfuusion mittaamiseksi |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| RU2325152C2 (ru) * | 2001-07-04 | 2008-05-27 | Сан Фармасьютикл Индастриз Лимитид | Удерживаемая в желудке система регулируемой доставки лекарственного средства |
| US20040010038A1 (en) * | 2002-02-27 | 2004-01-15 | Eran Blaugrund | Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors |
| US20040166159A1 (en) * | 2002-05-29 | 2004-08-26 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa |
| US20060009483A1 (en) * | 2002-05-31 | 2006-01-12 | Bayer Pharmaceuticals Corporation | Compounds and compositions for the treatment of diabetes and diabetes-related disorders |
| WO2004026453A2 (en) * | 2002-09-06 | 2004-04-01 | Genteric, Inc. | Microcapsules and methods of use |
| SI1567152T1 (sl) * | 2002-11-15 | 2013-10-30 | Teva Pharmaceutical Industries Ltd. | Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze |
| US20050026979A1 (en) * | 2003-07-31 | 2005-02-03 | Maha Ghazzi | Methods for treating inflammation and inflammation-associated diseases with a statin and ether |
| CA2901244A1 (en) * | 2005-02-23 | 2006-08-31 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations of improved content uniformity |
-
1995
- 1995-05-22 US US08/446,439 patent/US5744500A/en not_active Expired - Lifetime
-
1996
- 1996-05-14 IL IL11824796A patent/IL118247A/en not_active IP Right Cessation
- 1996-05-22 RU RU97121002/14A patent/RU2203653C2/ru not_active IP Right Cessation
- 1996-05-22 SK SK1574-97A patent/SK283675B6/sk unknown
- 1996-05-22 AU AU58723/96A patent/AU699090B2/en not_active Expired
- 1996-05-22 PL PL96323470A patent/PL184124B1/pl not_active IP Right Cessation
- 1996-05-22 US US08/952,705 patent/US6316504B1/en not_active Expired - Lifetime
- 1996-05-22 CA CA002221458A patent/CA2221458A1/en not_active Abandoned
- 1996-05-22 NZ NZ308866A patent/NZ308866A/en not_active IP Right Cessation
- 1996-05-22 EP EP96920401A patent/EP0828485A4/en not_active Ceased
- 1996-05-22 KR KR1019970708371A patent/KR100412154B1/ko not_active Expired - Fee Related
- 1996-05-22 CN CN96195710A patent/CN1096853C/zh not_active Expired - Fee Related
- 1996-05-22 CZ CZ19973699A patent/CZ288724B6/cs not_active IP Right Cessation
- 1996-05-22 HU HU9901629A patent/HUP9901629A3/hu unknown
- 1996-05-22 WO PCT/US1996/007465 patent/WO1996037199A1/en not_active Ceased
- 1996-05-22 BR BR9608733-1A patent/BR9608733A/pt not_active Application Discontinuation
- 1996-05-22 JP JP53584496A patent/JP3341898B2/ja not_active Expired - Fee Related
- 1996-05-22 EE EE9700310A patent/EE03741B1/xx not_active IP Right Cessation
- 1996-05-22 MX MX9708977A patent/MX9708977A/es unknown
-
1997
- 1997-11-20 NO NO975331A patent/NO975331L/no not_active Application Discontinuation
- 1997-12-22 LT LT97-200A patent/LT4455B/lt not_active IP Right Cessation
-
1998
- 1998-01-20 LV LVP-97-267A patent/LV12083B/en unknown
-
2001
- 2001-10-26 US US10/016,268 patent/US6630514B2/en not_active Expired - Fee Related
-
2002
- 2002-11-27 US US10/305,478 patent/US6956060B2/en not_active Expired - Fee Related
-
2005
- 2005-06-17 US US11/155,864 patent/US20060094783A1/en not_active Abandoned
-
2006
- 2006-11-10 US US11/595,726 patent/US20070100001A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0828485A4 (en) | USE OF THE R-ENANTIOMER OF N-PROPARGYL-1-AMINOINDANE, ITS SALTS AND COMPOSITIONS | |
| IL118825A (en) | Substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane derivatives their preparation and use | |
| MX192025B (en) | Cosmetic composition, preparation and application of same | |
| IL116851A0 (en) | 3-arylidene-2-oxindole derivatives their preparation and use | |
| NL300295I2 (nl) | 3,3-diarylpropylaminen, de toepassing en bereidinghiervan | |
| HUP0900587A3 (en) | Stable salts of 3,3-diphenylpropylamines and preparation thereof | |
| HUP9801817A3 (en) | Dolastatin derivatives, their preparation and use | |
| ZA971964B (en) | Azolobenzazepine derivatives and compositions and method of use thereof. | |
| GB9525812D0 (en) | Composition and use | |
| HUP9904694A3 (en) | Spiropyrrolidine derivatives, their use and pharmaceutical compositions containing them | |
| HUP9901685A3 (en) | Colchicine derivatives, the use thereof and formulations containing them | |
| IL117981A0 (en) | Compositions containing 2-oxetanones their preparation and use | |
| HUP0105075A3 (en) | 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives, their use and pharmaceutical compositions containing them | |
| HUP9801880A3 (en) | Novel cryptophycins, their use and pharmaceutical compositions containing them | |
| HUP0102025A3 (en) | Derivatives of 1,3,4-oxadiazolone, pharmaceutical compositions containing them and their use | |
| IL118443A0 (en) | Cycloalkane-benzylidene derivatives their preparation and use | |
| EP0852503A4 (en) | AGENTS FOR THE TREATMENT OF DIARRHÖ, THEIR USE AND PRODUCTION | |
| HUP9802590A3 (en) | Indan-, benzothiophene-, benzofuran- and indolesulfonamide derivatives, their use and pharmaceutical compositions containing them | |
| IL123092A0 (en) | Pyrazol-4-ylbenzoyl derivatives their preparation and use | |
| NZ323282A (en) | N,n'-bridged bisindolylmaleimides and their use to prepare n,n'-bridged bisindolylmaleimides | |
| HRP960400B1 (en) | New carbonic acid derivatives, their preparation and their use | |
| GB2324090B (en) | 5,6-O-alkylidene glucono-1(4)-lactones and derivatives thereof,their preparation and use | |
| IL118547A0 (en) | Aqueous film-formimg compositions and their use | |
| AU4605399A (en) | Novel 3,4-diaminophenol derivatives and their use | |
| GB9512703D0 (en) | Composition and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ND9D | Filing a supplementary protection certificate |
Free format text: PRODUCT NAME: RASAGILINUM (N-PROPARGIL-1-(R)-AMINOINDANO MEZILATAS); REGISTRY NO: EU//1/04/304/001-007; REGISTRY DATE: 20050221 Spc suppl protection certif: PA2005007 Filing date: 20050819 |
|
| SPCF | Filing an spc |
Free format text: PRODUCT NAME: RASAGILINUM (N-PROPARGIL-1-(R)-AMINOINDANO MEZILATAS); REGISTRATION NO/DATE: EU/1/04/304/001, EU/1/04/304/002, EU/1/04/304/003, EU/1/04/304/004, EU/1/04/304/005, EU/1/04/304/006, EU/1/04/304/007 20050221 Spc suppl protection certif: PA2005007 Filing date: 20050819 Expiry date: 20160522 |
|
| SPCG | Grant of an spc |
Free format text: PRODUCT NAME: RASAGILINUM (N-PROPARGIL-1-(R)-AMINOINDANO MEZILATAS); REGISTRATION NO/DATE: EU/1/04/304/001, EU/1/04/304/002, EU/1/04/304/003, EU/1/04/304/004, EU/1/04/304/005, EU/1/04/304/006, EU/1/04/304/007 20050221 Spc suppl protection certif: PA2005007,C4455 Filing date: 20050819 Expiry date: 20160522 Extension date: 20200222 |
|
| MK9A | Expiry of a patent |
Effective date: 20160522 |